Geneos Wealth Management Inc. Buys 1,626 Shares of Stryker Corporation $SYK

Geneos Wealth Management Inc. grew its stake in shares of Stryker Corporation (NYSE:SYK) by 7.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,958 shares of the medical technology company’s stock after acquiring an additional 1,626 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Stryker were worth $7,872,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in SYK. Sankala Group LLC bought a new position in Stryker during the fourth quarter valued at approximately $26,000. Godfrey Financial Associates Inc. bought a new stake in Stryker in the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new stake in Stryker during the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker during the 4th quarter valued at $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker during the 4th quarter valued at $28,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of research reports. Leerink Partners dropped their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. JPMorgan Chase & Co. lowered their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $392.52.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 323,264 shares of company stock valued at $100,659,489 over the last quarter. 4.60% of the stock is currently owned by company insiders.

Stryker Trading Up 4.5%

Shares of Stryker stock opened at $330.64 on Friday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company’s fifty day simple moving average is $312.00 and its 200-day simple moving average is $336.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The stock has a market capitalization of $126.76 billion, a PE ratio of 38.27, a P/E/G ratio of 2.03 and a beta of 0.77.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter last year, the company earned $2.84 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.